MX2020011744A - Molecula de polipeptido con especificidad dual mejorada. - Google Patents
Molecula de polipeptido con especificidad dual mejorada.Info
- Publication number
- MX2020011744A MX2020011744A MX2020011744A MX2020011744A MX2020011744A MX 2020011744 A MX2020011744 A MX 2020011744A MX 2020011744 A MX2020011744 A MX 2020011744A MX 2020011744 A MX2020011744 A MX 2020011744A MX 2020011744 A MX2020011744 A MX 2020011744A
- Authority
- MX
- Mexico
- Prior art keywords
- polypeptide molecule
- dual specificity
- improved dual
- binding region
- polypeptide chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C07K16/114—
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a una molécula de polipéptido biespecífica que comprende una primera cadena polipeptídica y una segunda cadena polipeptídica, que proporciona una región de unión derivada de un receptor de linfocito T (TCR) que es específica para un epítopo peptídico asociado al complejo principal de histocompatibilidad (MHC), y una región de unión derivada de un anticuerpo capaz de reclutar células efectoras inmunitarias humanas mediante la unión específica a un antígeno de superficie de dichas células, así como métodos para fabricar la molécula de polipéptido biespecífica, y usos de la misma.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762532713P | 2017-07-14 | 2017-07-14 | |
| DE102017115966.5A DE102017115966A1 (de) | 2017-07-14 | 2017-07-14 | Polypeptidmolekül mit verbesserter zweifacher Spezifität |
| DE102017119866 | 2017-08-30 | ||
| US201862658318P | 2018-04-16 | 2018-04-16 | |
| DE102018108995 | 2018-04-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020011744A true MX2020011744A (es) | 2021-01-08 |
Family
ID=62951983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020011744A MX2020011744A (es) | 2017-07-14 | 2020-01-14 | Molecula de polipeptido con especificidad dual mejorada. |
Country Status (28)
| Country | Link |
|---|---|
| US (8) | US20190016804A1 (es) |
| EP (3) | EP3428194B1 (es) |
| JP (4) | JP2020530762A (es) |
| KR (2) | KR102833184B1 (es) |
| CN (2) | CN110914308A (es) |
| AU (2) | AU2018298884A1 (es) |
| BR (2) | BR112020000762A2 (es) |
| CA (2) | CA3069842A1 (es) |
| CO (2) | CO2020001029A2 (es) |
| CR (2) | CR20200013A (es) |
| CY (2) | CY1124091T1 (es) |
| DK (2) | DK3428194T3 (es) |
| ES (2) | ES2898210T3 (es) |
| HR (1) | HRP20211744T1 (es) |
| HU (2) | HUE057110T2 (es) |
| LT (2) | LT3428194T (es) |
| MA (1) | MA46299B1 (es) |
| MD (2) | MD3428194T2 (es) |
| MX (1) | MX2020011744A (es) |
| PE (2) | PE20200615A1 (es) |
| PL (2) | PL3652215T3 (es) |
| PT (2) | PT3428194T (es) |
| RS (2) | RS62544B1 (es) |
| SG (2) | SG11202000027WA (es) |
| SI (2) | SI3428194T1 (es) |
| TW (2) | TWI817302B (es) |
| WO (2) | WO2019012138A1 (es) |
| ZA (1) | ZA202000842B (es) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| SG11202000027WA (en) | 2017-07-14 | 2020-02-27 | Immatics Biotechnologies Gmbh | Improved dual specificity polypeptide molecule |
| CA3100253A1 (en) | 2018-05-14 | 2019-11-21 | Immunocore Limited | Bifunctional binding polypeptides |
| GB201904328D0 (en) | 2019-03-28 | 2019-05-15 | Immunocore Ltd | Specific binding molecules |
| US11975025B2 (en) | 2019-05-27 | 2024-05-07 | Immatics US, Inc. | Viral vectors and use thereof in adoptive cellular therapy |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| US20210032370A1 (en) * | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| CN112409474B (zh) * | 2019-08-23 | 2023-02-28 | 香雪生命科学技术（广东）有限公司 | 一种识别ssx2抗原的高亲和力tcr |
| GB201915282D0 (en) | 2019-10-22 | 2019-12-04 | Immunocore Ltd | Specific binding molecules |
| US20230340119A1 (en) * | 2019-12-05 | 2023-10-26 | Arbele Corp | Composition of triax antibodies and method of making and using thereof |
| JP2023515131A (ja) | 2020-02-24 | 2023-04-12 | イマティクス ユーエス，アイエヌシー． | がんおよび関連する悪性腫瘍の治療のためにｔ細胞を増殖させる方法 |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| GB202006629D0 (en) | 2020-05-05 | 2020-06-17 | Immunocore Ltd | Specific binding molecules |
| GB202010329D0 (en) | 2020-07-06 | 2020-08-19 | Immunocore Ltd | Specific binding molecules |
| WO2022040631A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| PE20250846A1 (es) | 2020-12-31 | 2025-03-21 | Immatics Us Inc | Polipeptidos cd8, composiciones y metodos de uso de estos |
| WO2022184805A1 (en) | 2021-03-03 | 2022-09-09 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein |
| US12435444B2 (en) | 2021-03-09 | 2025-10-07 | Cdr-Life Ag | Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same |
| MX2023012902A (es) | 2021-05-05 | 2023-11-08 | Immatics Biotechnologies Gmbh | Proteinas de union a antigenos que se unen especificamente a prame. |
| EP4113120A1 (en) | 2021-06-28 | 2023-01-04 | Immatics Biotechnologies GmbH | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
| US20230024554A1 (en) | 2021-06-28 | 2023-01-26 | Immatics Biotechnologies Gmbh | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
| CA3226437A1 (en) | 2021-07-27 | 2023-02-02 | Sara Yousef | Antigen binding proteins specifically binding ct45 |
| CN117964777A (zh) * | 2021-08-26 | 2024-05-03 | 瑅安生物医药（杭州）有限公司 | 一种接近天然分子的多肽融合分子 |
| TW202332765A (zh) | 2021-09-20 | 2023-08-16 | 美商英麥提克斯股份有限公司 | 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡 |
| UY39967A (es) | 2021-10-06 | 2023-05-15 | Immatics Biotechnologies Gmbh | Indicaciones para los aglutinantes anti-PRAME |
| US20230192886A1 (en) | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| WO2023081461A1 (en) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Methods for generating cell spheroids |
| JP2024546875A (ja) * | 2021-12-14 | 2024-12-26 | シーディアール－ライフ・アクチェンゲゼルシャフト | 二連型ｍｈｃ標的化ｔ細胞エンゲージャー |
| EP4479423A1 (en) | 2022-02-20 | 2024-12-25 | Immunocore Limited | Hiv-specific binding molecules and tcr |
| IL316515A (en) | 2022-04-28 | 2024-12-01 | Immatics Us Inc | Membrane-bound IL15 CD8 proteins, cells, compositions and methods for their use |
| WO2023212655A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| JP2025515604A (ja) | 2022-04-28 | 2025-05-20 | イマティクス ユーエス，アイエヌシー． | ドミナントネガティブＴＧＦβ受容体ポリペプチド、ＣＤ８ポリペプチド、細胞、組成物、およびその使用方法 |
| US20250354995A1 (en) | 2022-04-29 | 2025-11-20 | Immatics Biotechnologies Gmbh | Mammalian display platform for multispecific antigen binding proteins |
| WO2023215825A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| WO2023240124A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
| EP4569324A1 (en) | 2022-08-08 | 2025-06-18 | Immatics Biotechnologies GmbH | Guided positional scanning method |
| CN120202015A (zh) | 2022-09-14 | 2025-06-24 | Cdr-生物科技股份有限公司 | Mage-a4肽双重t细胞衔接子 |
| WO2024130179A1 (en) | 2022-12-16 | 2024-06-20 | Repertoire Immune Medicines, Inc. | T cell receptors binding hpv-16 epitopes |
| WO2024146951A1 (en) | 2023-01-06 | 2024-07-11 | Immunocore Limited | Binding molecules against a prame peptide-hla complex |
| EP4646268A1 (en) | 2023-01-06 | 2025-11-12 | Immunocore Limited | Binding molecules against a piwil1 peptide-hla complex |
| WO2025008513A1 (en) | 2023-07-05 | 2025-01-09 | Immatics Biotechnologies Gmbh | A method of identifying mhc-binding proteins and interacting peptides in a sample |
| TW202506719A (zh) | 2023-07-27 | 2025-02-16 | 德商艾瑪提克生物技術有限公司 | 針對mageb2之抗原結合蛋白 |
| WO2025085855A2 (en) * | 2023-10-20 | 2025-04-24 | BioNTech SE | Multispecific t cell engagers compositions and methods of use thereof |
| WO2025087436A1 (zh) * | 2023-10-27 | 2025-05-01 | 北京可瑞生物科技有限公司 | 基于t细胞受体的多特异性多肽分子及其组合物和用途 |
| US20250134931A1 (en) | 2023-11-01 | 2025-05-01 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2025094054A1 (en) * | 2023-11-01 | 2025-05-08 | Immunocore Limited | Method for purifying small multi-domain proteins |
| GB202320012D0 (en) * | 2023-12-22 | 2024-02-07 | Immunocore Ltd | Bispecific molecules |
| WO2025233431A1 (en) | 2024-05-07 | 2025-11-13 | Immatics Biotechnologies Gmbh | Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof |
| GB2641580A (en) | 2024-06-07 | 2025-12-10 | T Therapeutics Ltd | Tumour-transforming multispecific proteins |
| WO2026025031A1 (en) | 2024-07-26 | 2026-01-29 | Modernatx, Inc. | Mrna encoding mageb2 tcer molecule |
| CN119529098B (zh) * | 2025-01-22 | 2025-05-30 | 北京可瑞生物科技有限公司 | 对mage-a1具有特异性的结合分子和抗cd3的融合蛋白 |
Family Cites Families (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2018248A1 (en) | 1989-06-07 | 1990-12-07 | Clyde W. Shearman | Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US8211422B2 (en) | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
| PT1231268E (pt) | 1994-01-31 | 2005-11-30 | Univ Boston | Bancos de anticorpos policlonais |
| IL132560A0 (en) | 1997-05-02 | 2001-03-19 | Genentech Inc | A method for making multispecific antibodies having heteromultimeric and common components |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| AU2001270609A1 (en) | 2000-06-30 | 2002-01-14 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
| DE60232672D1 (de) | 2001-10-01 | 2009-07-30 | Dyax Corp | Mehrkettige eukaryontische display-vektoren und deren verwendungen |
| CA2501870C (en) | 2002-10-09 | 2013-07-02 | Avidex Limited | Single chain recombinant t cell receptors |
| EP2985291B1 (en) | 2005-04-01 | 2018-09-19 | Immunocore Limited | High affinity hiv t cell receptors |
| US9284375B2 (en) | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| WO2006113665A2 (en) | 2005-04-15 | 2006-10-26 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| JP5956709B2 (ja) | 2005-05-27 | 2016-07-27 | オスペダーレ サン ラファエレ エス．アール．エル | 遺伝子ベクター |
| AT503861B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von t-zell-rezeptoren |
| US20100105136A1 (en) | 2006-10-09 | 2010-04-29 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
| US20110045007A1 (en) | 2007-05-31 | 2011-02-24 | Genmab A/S | Fusion or linked proteins with extended half life |
| CA2711806A1 (en) | 2008-01-11 | 2009-07-16 | Morphosys Ag | Display vectors and methods and uses thereof |
| EP2258719A1 (en) * | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
| CA2776143A1 (en) | 2009-10-01 | 2011-04-07 | The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| WO2011044186A1 (en) | 2009-10-06 | 2011-04-14 | The Board Of Trustees Of The University Of Illinois | Human single-chain t cell receptors |
| HUE029257T2 (en) | 2009-12-29 | 2017-02-28 | Aptevo Res And Dev Llc | Heterodimer binding proteins and their use |
| US20130129723A1 (en) | 2009-12-29 | 2013-05-23 | Emergent Product Development Seattle, Llc | Heterodimer Binding Proteins and Uses Thereof |
| WO2011085178A1 (en) | 2010-01-11 | 2011-07-14 | Trustees Of Dartmouth College | Monomeric bi-specific fusion protein |
| GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| MX349057B (es) | 2010-11-30 | 2017-07-07 | Chugai Pharmaceutical Co Ltd | Agente terapeutico que induce citotoxicidad. |
| EP2673300B1 (en) | 2011-02-11 | 2016-08-24 | Memorial Sloan-Kettering Cancer Center | Hla-restricted, peptide-specific antigen binding proteins |
| WO2013026837A1 (en) * | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
| CA2887486A1 (en) | 2012-11-30 | 2014-06-05 | Roche Glycart Ag | Removal of cancer cells by circulating virus-specific cytotoxic t-cells using cancer cell targeted mhc class i comprising multi-function proteins |
| EP2961771B1 (en) | 2013-02-26 | 2020-01-01 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules specific to cd3 and cea |
| HK1211299A1 (en) | 2013-02-26 | 2016-05-20 | 罗切格利卡特公司 | Bispecific t cell activating antigen binding molecules |
| SG10201705245TA (en) * | 2013-03-14 | 2017-07-28 | Macrogenics Inc | Bispecific Molecules That Are Immunoreactive With Immune Effector Cells That Express An Activating Receptor And An Antigen Expressed By A Cell Infected By A Virus And Uses Thereof |
| WO2015077891A1 (en) | 2013-11-27 | 2015-06-04 | Zymeworks Inc. | Bispecific antigen-binding constructs targeting her2 |
| EP3192812B1 (en) | 2013-12-17 | 2020-05-27 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| JP6405390B2 (ja) | 2014-03-25 | 2018-10-17 | メリアル インコーポレイテッド | 弱毒ヒストフィルス・ソムニを含む免疫学的組成物 |
| EP3172231B1 (en) | 2014-07-24 | 2021-05-05 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors |
| EP2985294A1 (en) | 2014-08-14 | 2016-02-17 | Deutsches Krebsforschungszentrum | Recombinant antibody molecule and its use for target cell restricted T cell activation |
| US10851149B2 (en) | 2014-08-14 | 2020-12-01 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using GFR α-4 chimeric antigen receptor |
| DK3221356T3 (da) | 2014-11-20 | 2020-11-02 | Hoffmann La Roche | T-celleaktiverende, bispecifikke, antigenbindende molekyler mod folr1 og cd3 |
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| GB201423361D0 (en) | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| GB201504502D0 (en) | 2015-03-17 | 2015-04-29 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |
| EP3270937A4 (en) | 2015-03-26 | 2018-09-12 | The Trustees Of Dartmouth College | Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| GB201505585D0 (en) | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
| GB201507030D0 (en) | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
| GB201507719D0 (en) | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| SG10201914069SA (en) | 2015-05-18 | 2020-03-30 | Tcr2 Therapeutics Inc | Compositions and methods for tcr reprogramming using fusion proteins |
| EP3095792A1 (en) * | 2015-05-19 | 2016-11-23 | Klinikum rechts der Isar der Technischen Universität München | T cell receptor with specificity for myeloperoxidase peptide and uses thereof |
| GB201510771D0 (en) | 2015-06-19 | 2015-08-05 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer |
| GB201511191D0 (en) | 2015-06-25 | 2015-08-12 | Immatics Biotechnologies Gmbh | T-cell epitopes for the immunotherapy of myeloma |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| GB201511792D0 (en) | 2015-07-06 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers |
| MY189596A (en) | 2015-07-15 | 2022-02-18 | Immatics Biotechnologies Gmbh | A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| GB201515321D0 (en) | 2015-08-28 | 2015-10-14 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| US20170136108A1 (en) | 2015-08-28 | 2017-05-18 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| GB201517538D0 (en) | 2015-10-05 | 2015-11-18 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| WO2017059900A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Cell & Gene Therapies Gmbh | Antigen receptors and uses thereof |
| WO2017060201A1 (en) | 2015-10-09 | 2017-04-13 | Immatics Biotechnologies Gmbh | Anti-wt1/hla-specific antibodies |
| SG10201913245UA (en) * | 2015-10-23 | 2020-02-27 | Eureka Therapeutics Inc | Antibody/t-cell receptor chimeric constructs and uses thereof |
| GB201521746D0 (en) | 2015-12-10 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
| GB201521894D0 (en) | 2015-12-11 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
| GB201522592D0 (en) * | 2015-12-22 | 2016-02-03 | Immunocore Ltd | T cell receptors |
| GB201522667D0 (en) | 2015-12-22 | 2016-02-03 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
| GB201602918D0 (en) | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| GB201603568D0 (en) | 2016-03-01 | 2016-04-13 | Immatics Biotechnologies Gmbh | Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer |
| GB201603987D0 (en) | 2016-03-08 | 2016-04-20 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| US11034767B2 (en) | 2016-04-15 | 2021-06-15 | Trustees Of Dartmouth College | High affinity B7-H6 antibodies and antibody fragments |
| EP3472208B9 (en) | 2016-06-17 | 2023-10-04 | Medigene Immunotherapies GmbH | T cell receptors and uses thereof |
| CN109643503A (zh) | 2016-06-27 | 2019-04-16 | 宝洁公司 | 由口腔护理产品评估牙齿过敏处理的设备和方法 |
| CN109715668A (zh) | 2016-08-02 | 2019-05-03 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重编程的组合物和方法 |
| JP7012364B2 (ja) | 2016-08-05 | 2022-02-14 | 国立大学法人東北大学 | Ｔ細胞受容体の認識機構を用いたがん又は感染症の治療及び診断 |
| US11453726B2 (en) | 2016-09-15 | 2022-09-27 | Quadrucept Bio Limited | Multimers, tetramers and octamers |
| CN106831996B (zh) * | 2017-03-31 | 2020-05-19 | 北京智仁美博生物科技有限公司 | 具有cd3e和/或her2靶向功能的双特异性抗体及其用途 |
| CN111094333A (zh) | 2017-06-01 | 2020-05-01 | 斯图加特大学 | 异源二聚化的Ig结构域 |
| SG11202000027WA (en) | 2017-07-14 | 2020-02-27 | Immatics Biotechnologies Gmbh | Improved dual specificity polypeptide molecule |
| CN109468278A (zh) | 2017-09-08 | 2019-03-15 | 科济生物医药（上海）有限公司 | 基因工程化的t细胞及应用 |
| JPWO2019151392A1 (ja) | 2018-01-31 | 2021-02-04 | 国立大学法人東北大学 | 抗原特異的ｍｈｃ発現調節法 |
| CA3100253A1 (en) | 2018-05-14 | 2019-11-21 | Immunocore Limited | Bifunctional binding polypeptides |
| EA202091977A1 (ru) | 2018-05-28 | 2021-02-09 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения |
| WO2020018715A1 (en) | 2018-07-17 | 2020-01-23 | Massachusetts Institute Of Technology | Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof |
| WO2020057610A1 (en) | 2018-09-20 | 2020-03-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel bispecific anti-ctla-4/pd-1 polypeptide complexes |
| GB201903767D0 (en) | 2019-03-19 | 2019-05-01 | Quadrucept Bio Ltd | Multimers, tetramers & octamers |
| GB201906685D0 (en) | 2019-05-13 | 2019-06-26 | Ultrahuman Six Ltd | Activatable protein constructs and uses thereof |
| MX2022000667A (es) | 2019-07-15 | 2022-07-21 | Neogene Therapeutics B V | Metodo para aislar genes tcr. |
| US20210032370A1 (en) * | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| CA3149939A1 (en) | 2019-09-06 | 2021-03-11 | Stephen J. Demarest | Proteins comprising t-cell receptor constant domains |
| WO2021058807A1 (en) | 2019-09-25 | 2021-04-01 | Universität Stuttgart | Trivalent binding molecules |
| KR20220069935A (ko) | 2019-09-27 | 2022-05-27 | 아게누스 인코포레이티드 | 이종이량체 단백질 |
| KR20220098379A (ko) | 2019-11-15 | 2022-07-12 | 그릿스톤 바이오, 인코포레이티드 | 공유 네오항원을 표적으로 하는 항원-결합 단백질 |
| EP4061827A1 (en) | 2019-11-18 | 2022-09-28 | BioNTech SE | Prame tcr receptors and uses thereof |
| JP2023507729A (ja) | 2019-12-17 | 2023-02-27 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 腫瘍抗原を標的とするｍａｎａボディおよび使用方法 |
| CN110964122B (zh) | 2019-12-24 | 2022-04-15 | 南京北恒生物科技有限公司 | T细胞受体融合蛋白及其用途 |
| WO2021188601A1 (en) | 2020-03-16 | 2021-09-23 | University Of Southern California | Methods to prevent, ameliorate and treat complications from viral infections |
| CN116194130A (zh) | 2020-03-16 | 2023-05-30 | 南加利福尼亚大学 | 新颖的抗原结合结构域和包含这些抗原结合结构域的合成抗原受体 |
| WO2021222576A1 (en) | 2020-05-01 | 2021-11-04 | A2 Biotherapeutics, Inc. | Pag1 fusion proteins and methods of making and using same |
| CN116171165A (zh) | 2020-06-10 | 2023-05-26 | 墨尔本大学 | Hiv-1抗体 |
| JP2023536100A (ja) | 2020-07-27 | 2023-08-23 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ | 代替の翻訳開始および翻訳停止に由来する多機能免疫グロブリンフォールドポリペプチド |
| AU2021356681A1 (en) | 2020-10-09 | 2023-05-18 | Eureka Therapeutics Inc. | Compositions targeting ndc80/mhc complexes and uses thereof |
| WO2022083668A1 (en) | 2020-10-21 | 2022-04-28 | Nanjing Legend Biotech Co., Ltd. | Use of a chimeric co-stimulatory receptor for cell therapy |
| JP2023554119A (ja) | 2020-12-21 | 2023-12-26 | ザイムワークス ビーシー インコーポレイテッド | 安定化されたｔｃｒコンストラクト及び使用方法 |
| IL305175A (en) | 2021-02-19 | 2023-10-01 | Angeles Therapeutics Inc | Single-chain and multi-chain synthetic antigen receptors for diverse immune cells |
-
2018
- 2018-07-13 SG SG11202000027WA patent/SG11202000027WA/en unknown
- 2018-07-13 KR KR1020207004219A patent/KR102833184B1/ko active Active
- 2018-07-13 LT LTEP18183508.3T patent/LT3428194T/lt unknown
- 2018-07-13 ES ES18183508T patent/ES2898210T3/es active Active
- 2018-07-13 SI SI201830456T patent/SI3428194T1/sl unknown
- 2018-07-13 AU AU2018298884A patent/AU2018298884A1/en not_active Abandoned
- 2018-07-13 KR KR1020207004221A patent/KR20200026995A/ko not_active Ceased
- 2018-07-13 WO PCT/EP2018/069151 patent/WO2019012138A1/en not_active Ceased
- 2018-07-13 HU HUE18183508A patent/HUE057110T2/hu unknown
- 2018-07-13 PE PE2020000058A patent/PE20200615A1/es unknown
- 2018-07-13 AU AU2018298881A patent/AU2018298881B2/en active Active
- 2018-07-13 US US16/035,429 patent/US20190016804A1/en not_active Abandoned
- 2018-07-13 HU HUE18740829A patent/HUE054568T2/hu unknown
- 2018-07-13 LT LTEP18740829.9T patent/LT3652215T/lt unknown
- 2018-07-13 CA CA3069842A patent/CA3069842A1/en active Pending
- 2018-07-13 MD MDE20190844T patent/MD3428194T2/ro unknown
- 2018-07-13 PT PT181835083T patent/PT3428194T/pt unknown
- 2018-07-13 MA MA46299A patent/MA46299B1/fr unknown
- 2018-07-13 DK DK18183508.3T patent/DK3428194T3/da active
- 2018-07-13 JP JP2020501174A patent/JP2020530762A/ja active Pending
- 2018-07-13 CN CN201880046726.5A patent/CN110914308A/zh active Pending
- 2018-07-13 US US16/035,412 patent/US20190016802A1/en not_active Abandoned
- 2018-07-13 ES ES18740829T patent/ES2871146T3/es active Active
- 2018-07-13 SI SI201830285T patent/SI3652215T1/sl unknown
- 2018-07-13 PL PL18740829T patent/PL3652215T3/pl unknown
- 2018-07-13 WO PCT/EP2018/069157 patent/WO2019012141A1/en not_active Ceased
- 2018-07-13 EP EP18183508.3A patent/EP3428194B1/en active Active
- 2018-07-13 BR BR112020000762-5A patent/BR112020000762A2/pt unknown
- 2018-07-13 RS RS20211381A patent/RS62544B1/sr unknown
- 2018-07-13 CR CR20200013A patent/CR20200013A/es unknown
- 2018-07-13 CN CN201880046721.2A patent/CN110914307A/zh active Pending
- 2018-07-13 US US16/035,420 patent/US20190016803A1/en not_active Abandoned
- 2018-07-13 EP EP18740829.9A patent/EP3652215B1/en active Active
- 2018-07-13 PE PE2020000056A patent/PE20200614A1/es unknown
- 2018-07-13 HR HRP20211744TT patent/HRP20211744T1/hr unknown
- 2018-07-13 EP EP21191794.3A patent/EP3985029A1/en active Pending
- 2018-07-13 US US16/035,403 patent/US11905328B2/en active Active
- 2018-07-13 CR CR20200014A patent/CR20200014A/es unknown
- 2018-07-13 RS RS20210561A patent/RS61817B1/sr unknown
- 2018-07-13 MD MDE20200533T patent/MD3652215T2/ro unknown
- 2018-07-13 CA CA3069610A patent/CA3069610A1/en active Pending
- 2018-07-13 SG SG11202000025SA patent/SG11202000025SA/en unknown
- 2018-07-13 PT PT187408299T patent/PT3652215T/pt unknown
- 2018-07-13 BR BR112020000769-2A patent/BR112020000769A2/pt not_active Application Discontinuation
- 2018-07-13 PL PL18183508T patent/PL3428194T3/pl unknown
- 2018-07-13 DK DK18740829.9T patent/DK3652215T3/da active
- 2018-07-16 TW TW110149543A patent/TWI817302B/zh not_active IP Right Cessation
- 2018-07-16 TW TW107124492A patent/TWI762677B/zh not_active IP Right Cessation
- 2018-07-17 JP JP2018134424A patent/JP6784724B2/ja active Active
-
2020
- 2020-01-14 MX MX2020011744A patent/MX2020011744A/es unknown
- 2020-01-28 CO CONC2020/0001029A patent/CO2020001029A2/es unknown
- 2020-02-10 ZA ZA2020/00842A patent/ZA202000842B/en unknown
- 2020-02-11 CO CONC2020/0001491A patent/CO2020001491A2/es unknown
-
2021
- 2021-05-06 CY CY20211100387T patent/CY1124091T1/el unknown
- 2021-11-01 CY CY20211100934T patent/CY1124835T1/el unknown
-
2022
- 2022-03-03 US US17/686,358 patent/US20220185888A1/en not_active Abandoned
- 2022-03-12 US US17/693,323 patent/US20220195044A1/en not_active Abandoned
-
2023
- 2023-05-22 JP JP2023083663A patent/JP2023103451A/ja active Pending
- 2023-06-08 US US18/331,556 patent/US20230348598A1/en not_active Abandoned
- 2023-11-24 JP JP2023198791A patent/JP2024023385A/ja active Pending
-
2025
- 2025-06-17 US US19/240,392 patent/US20250361300A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020011744A (es) | Molecula de polipeptido con especificidad dual mejorada. | |
| CO2017000506A2 (es) | Receptor quimérico de antígeno cll-1 | |
| UY36289A (es) | ANTICUERPOS MONOCLONALES QUE ENLAZAN INMUNOESPECIFICAMENTE A CD123 y COMPOSICIONES QUE LOS CONTIENEN | |
| UY35468A (es) | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 | |
| MX2017001011A (es) | Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma. | |
| BR112021019411A2 (pt) | Métodos para a produção de células car-nk e uso das mesmas | |
| MX2015010836A (es) | Tratamiento de cancer utilizando un receptor quimerico de antigeno anti egfrviii humanizado. | |
| CY1121673T1 (el) | Εξουδετερωση αντισωματων στις κυριες εξωτοξινες tcda και tcdb της λοιμωξης clostridium difficile | |
| MX2020010241A (es) | Composiciones de inmunoterapia celular y usos de las mismas. | |
| MX2016008076A (es) | Receptores quimericos de antigeno de mesotelina humana y uso de los mismos. | |
| MX2019012198A (es) | Constructos de polipéptidos multiespecíficos que tienen unión limitada a cd3 y métodos de utilización de los mismos. | |
| MX2019011897A (es) | Celulas efectoras inmunitarias especificas de antigenos. | |
| CO2017000510A2 (es) | Constructos de car | |
| MX2017002205A (es) | Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer. | |
| MY192682A (en) | Bispecific t cell engaging antibody constructs | |
| AR104718A1 (es) | Receptores de antígenos quiméricos específicos de anti-gd3 para inmunoterapias contra el cáncer | |
| CU20170023A7 (es) | Anticuerpos y receptores de antígeno quiméricos específicos para cd19 | |
| NI201700018A (es) | Anticuerpos anti-lag3 y fragmentos de unión a antígeno | |
| BR112017013981A2 (pt) | receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer | |
| TN2018000266A1 (en) | Psma and cd3 bispecific t cell engaging antibody constructs. | |
| PE20170263A1 (es) | Moleculas biespecificas de union a antigeno activadoras de celulas t | |
| MX2016012855A (es) | Receptores de antigeno quimerico especifico de cd33 para inmunoterapia de cancer. | |
| CO2020014343A2 (es) | Anticuerpos específicos para cd3 y sus usos | |
| MX2018013222A (es) | Anticuerpos de interferon beta y usos de los mismos. | |
| AR112228A1 (es) | Molécula de polipéptido con especificidad dual mejorada |